Licensing and Commercialization Agreements - Zimura License Agreement With Archemix Corp. (Details) - Archemix - C5 Licensed Product - License Agreements	1 Months Ended			8 Months Ended
	Oct. 31, 2020 USD ($)	Mar. 31, 2020 USD ($)	Sep. 30, 2011 USD ($) shares	Oct. 31, 2020 USD ($) milestone_payment	Dec. 31, 2022 USD ($)
Agreement
Licensing agreement term			12 years
Achievement of Specified Clinical and Regulatory Milestones
Agreement
Payments for license fees	$ 6,000,000	$ 1,000,000	$ 1,000,000	$ 9,000,000
Number of milestone payments | milestone_payment				2
Trial data period				12 months
Amount to be paid on achievement of milestone					$ 50,500,000
Achievement of Specified Clinical and Regulatory Milestones | Maximum
Agreement
Amount to be paid on achievement of milestone			$ 50,500,000
Achievement of Specified Clinical and Regulatory Milestones | Series A Preferred Stock
Agreement
Shares issued for license fees (in shares) | shares			2,000,000
Achievement of Specified Clinical and Regulatory Milestones | Series B Preferred Stock
Agreement
Shares issued for license fees (in shares) | shares			500,000
First Indication
Agreement
Amount to be paid on achievement of milestone			$ 24,500,000		24,500,000
Second and Third Indication
Agreement
Amount to be paid on achievement of milestone			23,500,000		23,500,000
Sustained Delivery Applications
Agreement
Amount to be paid on achievement of milestone			2,500,000		2,500,000
Achievement of Specified Commercial Milestones
Agreement
Amount to be paid on achievement of milestone					$ 22,500,000
Achievement of Specified Commercial Milestones | Maximum
Agreement
Amount to be paid on achievement of milestone			$ 22,500,000